Details About Generic Salt ::  Meloxica

Main Medicine Class:: Analgesic,NSAID   

(mell-ox-ih-kam)
Mobic
Class: Analgesic/NSAID

 

Drugs Class ::

 Action Decreases inflammation, pain, and fever, probably through inhibition of cyclooxygenase activity and prostaglandin synthesis.

Indications for Drugs ::

 Indications Relief of signs and symptoms of osteoarthritis.

Drug Dose ::

 Route/Dosage

7.5 to 15 mg once daily (maximum 15 mg/day).

Contraindication ::

 Contraindications Hypersensitivity to aspirin or any other NSAID.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established. Elderly: Use with caution. Cardiovascular disease: Since fluid retention and edema can occur; use with caution in patients with fluid retention, hypertension, or heart failure. GI effects: Serious GI toxicity (eg, bleeding, ulceration, perforation) can occur at any time, with or without warning signs. Hepatic impairment: Assess liver function while on therapy. Renal impairment: Assess function before and during therapy because NSAID metabolites are eliminated by the kidney.

PATIENT CARE CONSIDERATIONS


Drug Side Effects ::

 Adverse Reactions

CV: Arrhythmia; palpitation; tachycardia. DERM: Rash; pruritus; alopecia; angioedema; bullous eruption; erythema multiforme; photosensitivity; Stevens-Johnson syndrome; sweating; toxic epidermal necrolysis; urticaria. EENT: Pharyngitis; esophagitis; abnormal vision; conjunctivitis; taste perversion; innitus. GI: Abdominal pain; diarrhea; nausea; constipation; dyspepsia; flatulence; omiting; colitis; dry mouth; duodenal ulcer; eructation; gastric ulcer; intestinal perforation; melena; pancreatitis; perforated duodenal and gastric ulcers; lcerative stomatitis. GU: Micturition frequency; urinary tract infection; albuminuria; increased BUN and creatinine; hematuria; interstitial nephritis; renal failure. HEMA: Anemia; agranulocytosis; leukopenia; purpura; thrombocytopenia; ilirubinemia. HEPA: Increased ALT and AST; hepatitis; jaundice; liver failure. META: Edema; dehydration. RESP: Upper respiratory tract infection; coughing; asthma; bronchospasm; yspnea. OTHER: Falling; flu-like symptoms; pain; arthralgia; back pain; anaphylactoid reactions.

Drug Mode of Action ::  

 Action Decreases inflammation, pain, and fever, probably through inhibition of cyclooxygenase activity and prostaglandin synthesis.

Drug Interactions ::

 Interactions

ACE inhibitors (eg, captopril): Antihypertensive effects may be decreased. Aspirin: Additive GI toxicity. Cholestyramine: Plasma levels of meloxicam may be reduced. Loop diuretics (eg, furosemide), thiazide diuretics (eg, chlorothiazide): Diuretic effects may be decreased. Lithium: May increase lithium levels. Warfarin: May increase risk of gastric erosion and bleeding. Lab Test Interferences: None well documented.

 Adverse Reactions

CV: Arrhythmia; palpitation; tachycardia. DERM: Rash; pruritus; alopecia; angioedema; bullous eruption; erythema multiforme; photosensitivity; Stevens-Johnson syndrome; sweating; toxic epidermal necrolysis; urticaria. EENT: Pharyngitis; esophagitis; abnormal vision; conjunctivitis; taste perversion; innitus. GI: Abdominal pain; diarrhea; nausea; constipation; dyspepsia; flatulence; omiting; colitis; dry mouth; duodenal ulcer; eructation; gastric ulcer; intestinal perforation; melena; pancreatitis; perforated duodenal and gastric ulcers; lcerative stomatitis. GU: Micturition frequency; urinary tract infection; albuminuria; increased BUN and creatinine; hematuria; interstitial nephritis; renal failure. HEMA: Anemia; agranulocytosis; leukopenia; purpura; thrombocytopenia; ilirubinemia. HEPA: Increased ALT and AST; hepatitis; jaundice; liver failure. META: Edema; dehydration. RESP: Upper respiratory tract infection; coughing; asthma; bronchospasm; yspnea. OTHER: Falling; flu-like symptoms; pain; arthralgia; back pain; anaphylactoid reactions.

 Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established. Elderly: Use with caution. Cardiovascular disease: Since fluid retention and edema can occur; use with caution in patients with fluid retention, hypertension, or heart failure. GI effects: Serious GI toxicity (eg, bleeding, ulceration, perforation) can occur at any time, with or without warning signs. Hepatic impairment: Assess liver function while on therapy. Renal impairment: Assess function before and during therapy because NSAID metabolites are eliminated by the kidney.

PATIENT CARE CONSIDERATIONS


 Administration/Storage

 Assessment/Interventions

OVERDOSAGE: SIGNS & SYMPTOMS
  Lethargy, drowsiness, nausea, vomiting, epigastric pain, GI bleeding, hypertension, acute renal failure, hepatic dysfunction, respiratory depression, coma, convulsions, cardiovascular collapse, cardiac arrest

 Patient/Family Education

Drug Assesment ::

 Assessment/Interventions

OVERDOSAGE: SIGNS & SYMPTOMS
  Lethargy, drowsiness, nausea, vomiting, epigastric pain, GI bleeding, hypertension, acute renal failure, hepatic dysfunction, respiratory depression, coma, convulsions, cardiovascular collapse, cardiac arrest

Drug Storage/Management ::

 Administration/Storage

Drug Notes ::

 Patient/Family Education

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

We would like to keep you updated with special notifications.